How much does silibinin A reduce liver enzymes?

Meta-analysis data shows silibinin A reduces ALT levels with a standardized mean difference of -1.48 (95% CI -2.09 to -0.87) in alcoholic liver disease patients. This represents clinically meaningful improvement in liver function markers across multiple studies.

What is the difference between silibinin A and silymarin?

Silibinin A is a specific purified flavonolignan compound, while silymarin is a complex mixture containing silibinin A, silibinin B, silychristin, and silydianin. Silibinin A represents the most bioactive component of the silymarin complex.

Can silibinin A help with liver fibrosis?

Research indicates silibinin A may reduce liver fibrosis by inhibiting TGF-β1 mRNA expression, a key pathway in fibrotic tissue formation. However, clinical evidence for anti-fibrotic effects requires further validation in controlled trials.

Is silibinin A effective for non-alcoholic liver disease?

Current strong evidence specifically supports silibinin A use in alcoholic liver disease based on 15 RCTs. Evidence for non-alcoholic fatty liver disease or other liver conditions is limited and requires additional clinical validation.

How does silibinin A work at the molecular level?

Silibinin A functions through multiple pathways including TGF-β1 mRNA inhibition for anti-fibrotic effects and modulation of liver enzymes ALT, AST, and alkaline phosphatase. These mechanisms contribute to hepatoprotective and anti-inflammatory activity in liver tissue.

What is the optimal dosage of silibinin A for liver disease?

Clinical trials investigating silibinin A for liver disease have typically used dosages ranging from 420–800 mg daily in divided doses, though optimal dosing remains dependent on the specific liver condition and severity. The 15 randomized controlled trials examining alcoholic liver disease used varied protocols, making a universal recommendation difficult without individualized medical guidance. Consult a healthcare provider to determine appropriate dosing based on your specific condition and concurrent medications.

Does silibinin A interact with medications used to treat liver disease or other conditions?

Silibinin A may interact with cytochrome P450 metabolism since silymarin (of which silibinin A is a component) has been shown to affect drug-metabolizing enzymes, potentially impacting medications metabolized through these pathways. Specific interaction data for silibinin A in isolation is limited compared to whole silymarin extracts, making it important to disclose supplementation to healthcare providers. Those taking anticoagulants, anticonvulsants, or immunosuppressants should particularly discuss silibinin A use with their physician before starting supplementation.

Is silibinin A effective specifically for alcoholic liver disease compared to other liver conditions?

Evidence is strongest for silibinin A in alcoholic liver disease, with 15 randomized controlled trials (n=1,221) showing significant reductions in ALT levels (SMD=-1.48), suggesting meaningful benefit for this population. While silibinin A also shows promise in non-alcoholic fatty liver disease and fibrosis reduction through TGF-β1 inhibition, the quantity and quality of research is substantially greater for alcohol-related liver injury. Patients with alcoholic liver disease appear to represent the most well-supported use case based on current clinical evidence.

Silibinin A

Silibinin A is a flavonolignan compound derived from milk thistle that primarily supports liver function through hepatoprotective mechanisms. This bioactive compound demonstrates significant efficacy in reducing liver enzyme markers and inflammatory pathways associated with liver disease.

Category: Compound Evidence: 2/10 Tier: Moderate

Origin & History

Silibinin A is a stereoisomer of silibinin, the primary active flavonolignan found in silymarin, extracted from the seeds of the milk thistle (*Silybum marianum*), a plant native to the Mediterranean region. It is typically extracted using solvent-based methods and purified to be part of standardized silymarin extracts.

Historical & Cultural Context

Silibinin, as part of silymarin from milk thistle, has been used in European traditional medicine for thousands of years, primarily for its liver protective properties. Its use in herbal medicine underscores a rich history of supporting liver health.

Health Benefits

• May improve liver function in alcoholic liver disease (15 RCTs, n=1,221; SMD=-1.48 for ALT, 95% CI -2.09 to -0.87).[2]
• Shows potential in reducing fibrosis in liver disease by inhibiting TGF-β1 mRNA.[2]
• Can lower AST and AKP levels in patients with pulmonary tuberculosis, though not significantly affecting DILI incidence.[1]
• Exhibits anti-cancer properties in preclinical studies by targeting STAT3 to improve cancer therapeutics.[3][9]
• Traditionally used for hepato-protection in herbal medicine, supporting liver health for thousands of years.[4][6]

How It Works

Silibinin A exerts hepatoprotective effects primarily through inhibition of TGF-β1 mRNA expression, reducing liver fibrosis progression. The compound modulates liver enzyme activity, specifically reducing alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels through antioxidant and anti-inflammatory pathways. It also demonstrates activity against alkaline phosphatase (AKP) elevation in certain conditions.

Scientific Research

A significant open-label trial with 568 patients investigated silibinin for preventing drug-induced liver injury but found no significant difference in incidence. A meta-analysis of 15 RCTs with 1,221 participants showed improvements in liver function in alcoholic liver disease. However, cancer and cardiovascular studies remain limited by small sample sizes and lack of comprehensive data (PMIDs: 20015009, 35631363, 34209829).

Clinical Summary

Meta-analysis of 15 randomized controlled trials involving 1,221 participants shows silibinin A significantly reduces ALT levels in alcoholic liver disease patients (SMD=-1.48, 95% CI -2.09 to -0.87). The compound demonstrates measurable reductions in AST and alkaline phosphatase levels in pulmonary tuberculosis patients, though these changes were not statistically significant. Current evidence is strongest for liver enzyme reduction in alcoholic liver disease, with emerging research on fibrosis reduction through TGF-β1 pathway inhibition.

Nutritional Profile

Silibinin A is a pure isolated flavonolignan compound, not a whole food or nutritional source, and therefore contains no macronutrients (protein, fat, carbohydrates), fiber, vitamins, or minerals in any meaningful dietary sense. Bioactive compound profile: Silibinin A is one of the two diastereomers of silibinin (also called silybin), the primary active constituent isolated from silymarin extract of Silybum marianum (milk thistle seed). Silibinin A and Silibinin B together typically comprise approximately 50-70% of total silymarin content in standardized milk thistle extracts. As a pure compound, it has a molecular weight of 482.44 g/mol and molecular formula C25H22O10. Concentration in standardized silymarin extracts: silymarin typically contains 20-40 mg/g of combined silybin A+B in pharmaceutical-grade preparations. Clinical formulations such as Legalon and Siliphos (phytosome complex) are standardized to deliver 70-80% silymarin, of which silibinin A constitutes roughly 20-30% by weight. Bioavailability notes: oral bioavailability of free silibinin A is poor (~0.5-1%) due to low aqueous solubility and first-pass metabolism; phosphatidylcholine complexes (phytosomes) improve bioavailability by approximately 4.6-fold compared to unformulated silymarin; peak plasma concentration (Cmax) achieved at approximately 1-4 hours post-ingestion in phospholipid complex formulations. No caloric value, glycemic index, or nutrient density metrics are applicable to this compound.

Preparation & Dosage

Clinically, a dose of 70 mg silibinin capsules taken orally 3 times per day (210 mg/day) for 8 weeks has been studied for DILI prevention. Meta-analyzed RCTs in ALD used varying doses with standard care for 3-48 weeks. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Resveratrol, Quercetin, Green Tea Extract, N-Acetylcysteine

Safety & Interactions

Silibinin A is generally well-tolerated with minimal reported adverse effects in clinical trials. No significant drug interactions have been documented in current literature, though theoretical interactions with hepatically-metabolized medications may exist. Contraindications and pregnancy safety data are limited, requiring caution in these populations. Long-term safety profiles require further investigation given the limited duration of existing clinical studies.